64 results found.

Chemotherapy-Induced Nausea and Vomiting Clinical Trial using Fosaprepitant dimeglumine; Fosaprepitant Placebo; Dexamethasone; Ondansetron; Dexamethasone Placebo; Ondansetron Placebo; Rescue Therapy

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy.
Fosaprepitant dimeglumine; Fosaprepitant Placebo; Dexamethasone; Ondansetron; Dexamethasone Placebo; Ondansetron Placebo; Rescue Therapy

Diabetes Mellitus, Type 2 Clinical Trial using Metformin; Sitagliptin / Metformin; Placebo to Metformin; Placebo to Sitagliptin / Metformin

Merck Sharp & Dohme Corp. - Recruiting 10 years to 17 years.
- A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A (A Fixed-Dose Combination Tablet of Sitagliptin and Metformin) in Pediatric Patients With Type 2 Diabetes Mellitus.
Metformin; Sitagliptin / Metformin; Placebo to Metformin; Placebo to Sitagliptin / Metformin

Chemotherapy-induced Nausea and Vomiting Clinical Trial using Fosaprepitant 150 mg; Fosaprepitant 60 mg; Fosaprepitant 20 mg; Placebo Fosaprepitant; Ondansetron

Merck Sharp & Dohme Corp. - Recruiting N/A to 17 years.
- A Phase IIb, Partially-Blinded, Randomized, Active Comparator-Controlled Study to Evaluate the Pharmacokinetics/Pharmacodynamics, Safety, and Tolerability of Fosaprepitant in Pediatric Patients for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Emetogenic Chemotherapy.
Fosaprepitant 150 mg; Fosaprepitant 60 mg; Fosaprepitant 20 mg; Placebo Fosaprepitant; Ondansetron

Asthma Clinical Trial using MK-1029 10 mg; MK-1029 30 mg; MK-1029 150 mg; Montelukast 10 mg; Placebo; MK-1029 1 mg or 3 mg; Montelukast 10 mg + MK-1029

Merck Sharp & Dohme Corp. - Recruiting 18 years to 65 years.
- A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group, Adaptive-Design, Dose-Ranging Study of MK-1029 in Adult Subjects With Persistent Asthma.
MK-1029 10 mg; MK-1029 30 mg; MK-1029 150 mg; Montelukast 10 mg; Placebo; MK-1029 1 mg or 3 mg; Montelukast 10 mg + MK-1029

Type 2 Diabetes Mellitus Clinical Trial using MK-0431A XR; Placebo to MK-0431A XR; Metformin XR; Placebo to metformin XR; Insulin glargine

Merck Sharp & Dohme Corp. - Recruiting 10 years to 17 years.
- A Phase III Multicenter, Double-blind, Randomized, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A XR (a Fixed-dose Combination Tablet of Sitagliptin and Extended-release Metformin) in Pediatric Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy.
MK-0431A XR; Placebo to MK-0431A XR; Metformin XR; Placebo to metformin XR; Insulin glargine

Type 2 Diabetes Mellitus Clinical Trial using MK-3102; Placebo

Merck Sharp & Dohme Corp. - Recruiting 40 years or older.
- A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Subjects With Type 2 Diabetes Mellitus.
MK-3102; Placebo

Myelodysplastic Syndromes, or Leukemia, Myelomonocytic, Chronic Clinical Trial using Azacitidine; Volasertib

Boehringer Ingelheim - Recruiting 18 years or older.
- An Open Label Phase I Dose Escalation Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics and Efficacy of Intravenous Volasertib in Combination With Subcutaneous Azacitidine in Patients With Previously Untreated High-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) Ineligible for High-intensity Therapy.
Azacitidine; Volasertib

Disorder Related to Bone Marrow Transplantation, Leukemia, or Tra Clinical Trial using Fludarabine; Clofarabine; Busulfan; Thymoglobulin; Stem Cell Infusion; Tacrolimus; Methotrexate

M.D. Anderson Cancer Center - Recruiting 3 years to 70 years.
- A Randomized Study of Once Daily Fludarabine-Clofarabine Versus Fludarabine Alone Combined With Intervenous Busulfan Followed by Allogeneic Hemopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).
Fludarabine; Clofarabine; Busulfan; Thymoglobulin; Stem Cell Infusion; Tacrolimus; Methotrexate

Urinary Tract Infections, or Pyelonephritis Clinical Trial using MK-7655 250 mg with imipenem/cilastatin; MK-7655 125 mg with imipenem/cilastatin; imipenem/cilastatin 500 mg; Placebo to MK-7655

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase II, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone in Patients With Complicated Urinary Tract Infection (cUTI).
MK-7655 250 mg with imipenem/cilastatin; MK-7655 125 mg with imipenem/cilastatin; imipenem/cilastatin 500 mg; Placebo to MK-7655

Intra-abdominal Infections Clinical Trial using MK-7655 250 mg with imipenem/cilastatin; MK-7655 125 mg with imipenem/cilastatin; imipenem/cilastatin with placebo; Matching placebo to MK-7655

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase II, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone in Patients With Complicated Intra-Abdominal Infection [cIAI].
MK-7655 250 mg with imipenem/cilastatin; MK-7655 125 mg with imipenem/cilastatin; imipenem/cilastatin with placebo; Matching placebo to MK-7655

Candidiasis, Invasive Clinical Trial using Caspofungin; Amphotericin B Deoxycholate

Merck Sharp & Dohme Corp. - Recruiting N/A to 3 Months.
- A Multicenter, Double-Blind, Randomized, Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Versus Amphotericin B Deoxycholate in the Treatment of Invasive Candidiasis in Neonates and Infants Less Than 3 Months of Age.
Caspofungin; Amphotericin B Deoxycholate

Clostridium Difficile Infection Clinical Trial using MK-3415; MK-6072; MK-3415A; Placebo; SOC

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase III, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of the Efficacy, Safety, and Tolerability of a Single Infusion of MK-3415 (Human Monoclonal Antibody to Clostridium Difficile Toxin A), MK-6072 (Human Monoclonal Antibody to Clostridium Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to Clostridium Difficile Toxin A and Toxin B) in Patients Receiving Antibiotic Therapy for Clostridium Difficile Infection (MODIFY I).
MK-3415; MK-6072; MK-3415A; Placebo; SOC

Leukemia Clinical Trial using Eltrombopag; Hypomethylating Agent (HMA)

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Phase II Study of Eltrombopag With or Without Continuation of Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS).
Eltrombopag; Hypomethylating Agent (HMA)

Leukemia Clinical Trial using Ruxolitinib

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Phase I Study of Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS).
Ruxolitinib

Leukemia Clinical Trial using Cladribine; Cytarabine; Decitabine

M.D. Anderson Cancer Center - Recruiting 60 years or older.
- Phase II Study of Cladribine Plus Low Dose Cytarabine (LDAC) Induction Followed By Consolidation With Cladribine Plus LDAC Alternating With Decitabine in Patients With Untreated Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS).
Cladribine; Cytarabine; Decitabine

Hepatitis B, Chronic Clinical Trial using PEG-IntronT; PEGASYST

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Multicenter Open-label Study to Evaluate the Safety and Efficacy of PEG-IntronT Versus PEGASYST in Subjects With HBeAg Positive Chronic Hepatitis B and HBeAg Negative Chronic Hepatitis B Protocol No. MK-4031-376-00 (Also Known as SCH 054031, P08450).
PEG-IntronT; PEGASYST

Acute Myeloid Leukemia (AML), or Myelodysplastic Syndrome (MDS) Clinical Trial using Treosulfan

Center for International Blood and Marrow Transplant Research - Recruiting N/A to 21 years.
- A Phase II Study of Treosulfan/Fludarabine/Low Dose Total Body Irradiation as a Preparative Regimen for Children With AML/MDS Undergoing Allogeneic Hematopoietic Cell Transplantation.
Treosulfan

Acute Myeloid Leukemia (AML), or Myelodysplastic Syndrome (MDS) Clinical Trial

Fred Hutchinson Cancer Research Center - Recruiting 18 years to 80 years.
- Feasibility and Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) Compared to Conventional Chemotherapy for Older and Medically Infirm Patients Diagnosed With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes: A Prospective Observational Study.

Myelodysplastic Syndrome Clinical Trial using Oral Azacitidine; Placebo

Celgene Corporation - Recruiting 18 years or older.
- A Phase 3, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Subjects With Red Blood Cell Transfusion-dependent Anemia and Thrombocytopenia Due to IPSS Lower-risk Myelodysplastic Syndromes.
Oral Azacitidine; Placebo

Myelodysplastic Syndromes (MDS), or Acute Myelogenous Leukemia (A Clinical Trial using low dose 5'-azacitidine

Memorial Sloan-Kettering Cancer Center - Recruiting 1 year to 75 years.
- A Single Arm Phase II Trial of Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse.
low dose 5'-azacitidine

Acute Myeloid Leukemia With Multilineage Dysplasia Following Myel Clinical Trial using fludarabine phosphate; cyclophosphamide; total-body irradiation; iodine I 131 monoclonal antibody BC8; allogeneic bone marrow transplantation; tacrolimus; mycophenolate mofetil

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- Hematopoietic Bone Marrow Transplantation for Patients With High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using Related HLA-Mismatched Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined With Immunosuppression Before and After Transplantation.
fludarabine phosphate; cyclophosphamide; total-body irradiation; iodine I 131 monoclonal antibody BC8; allogeneic bone marrow transplantation; tacrolimus; mycophenolate mofetil

Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic L Clinical Trial using Sotatercept

Celgene Corporation - Recruiting 18 years or older.
- An Open-label, Randomized, Phase 2, Parallel, Dose-ranging, Multicenter Study of Sotatercept for the Treatment of Patients With Anemia and Low- or Intermediate-1 Risk Myelodysplastic Syndromes or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)..
Sotatercept

Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Clinical Trial using standard follow-up care; medical chart review; quality-of-life assessment

Fred Hutchinson Cancer Research Center - Recruiting 18 years to 75 years.
- Phase 2 Study of Early Discharge and Outpatient Management of Adult Patients Following Intensive Chemotherapy for MDS and Non-APL AML.
standard follow-up care; medical chart review; quality-of-life assessment

Myeldysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia, B Clinical Trial using Clofarabine; Lenalidomide

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Clofarabine Followed by Lenalidomide for Treatment of High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Clofarabine; Lenalidomide

MDS Clinical Trial using Darbepoetin alfa; Placebo

Amgen - Recruiting 18 years or older.
- A Multicenter, Randomised, Double-blind, Placebo-controlled Study of Darbepoetin Alfa for the Treatment of Anaemic Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS).
Darbepoetin alfa; Placebo

Myelodysplastic Syndrome Clinical Trial using pracinostat; Placebo; Azacitidine

MEI Pharma, Inc. - Recruiting 18 years or older.
- A Phase 2 Randomized Double-Blind Placebo-Controlled Study of Pracinostat in Combination With Azacitidine in Patients With Previously Untreated International Prognostic Scoring System (IPSS) Intermediate Risk-2 or High-Risk Myelodysplastic Syndrome (MDS).
pracinostat; Placebo; Azacitidine

Myelodysplastic Syndromes, or Thrombocytopenia Clinical Trial using Eltrombopag

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R Agonist), Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS).
Eltrombopag

Myelodysplastic Syndrome (MDS), Hematologic Neoplasms, Hematologi Clinical Trial using Cord Blood Transplant

National Institutes of Health Clinical Center (CC) - Recruiting N/A or older.
- A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications.
Cord Blood Transplant

Aplastic Anemia, Leukemia, Myelodysplastic Syndrome (MDS), or Lym Clinical Trial using Cord Blood Units

National Institutes of Health Clinical Center (CC) - Recruiting N/A or older.
- A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients.
Cord Blood Units

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adul Clinical Trial using pretargeted radioimmunotherapy; cyclosporine; mycophenolate mofetil; total-body irradiation; nonmyeloablative allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; fludarabine phosphate; pharmacological study

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- Hematopoietic Cell Transplantation for Patients With High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using Radiolabeled DOTA-Biotin Pretargeted by BC8 Antibody-Streptavidin Conjugate.
pretargeted radioimmunotherapy; cyclosporine; mycophenolate mofetil; total-body irradiation; nonmyeloablative allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; fludarabine phosphate; pharmacological study

Myelodysplastic Syndrome Clinical Trial using TL32711; 5-Azacitidine

TetraLogic Pharmaceuticals - Recruiting 18 years or older.
- A Phase 1b/2a, Open-label, Non-randomized Study of Birinapant in Combination With 5-azacitidine in Subjects With Myelodysplastic Syndrome Who Are Na‹ve, Refractory or Have Relapsed to 5-azacitidine Therapy.
TL32711; 5-Azacitidine

Leukemia Clinical Trial using Quizartinib; Cytarabine; AZA

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Phase I/II Study of the Combination of Quizartinib (AC220) With 5-Azacytidine or Low-Dose Cytarabine for the Treatment of Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Phase I/Phase II.
Quizartinib; Cytarabine; AZA

Myeloproliferative Disorders, Blood Cancer, or Myelodysplastic Sy Clinical Trial using Total Lymphoid Irradiation (TLI); Anti-Thymocyte Globulin as Conditioning (ATG)

Stanford University - Recruiting 49 years to 75 years.
- Total Lymphoid Irradiation and Anti-Thymocyte Globulin as Conditioning for Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for the Treatment of Myelodysplastic Syndromes and Myeloproliferative Disorders (Except CML).
Total Lymphoid Irradiation (TLI); Anti-Thymocyte Globulin as Conditioning (ATG)

Asthma Clinical Trial using Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 25 mcg; Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 50 mcg; Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 100 mcg; Mometasone Furoate (MF) Dry Powder Inhaler (DPI), 100 mcg; Placebo Metered Dose Inhaler (MDI); Placebo Dry Powder Inhaler (DPI)

Merck Sharp & Dohme Corp. - Recruiting 5 years to 11 years.
- A 12-Week, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Mometasone Furoate Metered Dose Inhaler in the Treatment of Children Ages 5 to 11 Years With Persistent Asthma.
Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 25 mcg; Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 50 mcg; Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 100 mcg; Mometasone Furoate (MF) Dry Powder Inhaler (DPI), 100 mcg; Placebo Metered Dose Inhaler (MDI); Placebo Dry Powder Inhaler (DPI)

Systemic Lupus Erythematosus (SLE) Clinical Trial using Acthar; Placebo for Acthar

Questcor Pharmaceuticals, Inc. - Recruiting 18 years or older.
- A Two-part Study Exploring the Efficacy, Safety, and Pharmacodynamics of Acthar in Systemic Lupus Erythematosus Patients With a History of Persistently Active Disease.
Acthar; Placebo for Acthar

Herpes Zoster Clinical Trial using V212; Placebo

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients With Solid Tumor or Hematologic Malignancy.
V212; Placebo

Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML); Clinical Trial using CliniMACS CD34+ Reagent System; Thiotepa; Cyclophosphamide; Alemtuzumab; Tacrolimus; Melphalan; Busulfan; Fludarabine

Columbia University - Recruiting N/A to 22 years.
- CD34+ Stem Cell Selection for Patients Receiving a Matched or Partially Matched Family or Unrelated Adult Donor Allogeneic Stem Cell Transplant for Malignant Disease.
CliniMACS CD34+ Reagent System; Thiotepa; Cyclophosphamide; Alemtuzumab; Tacrolimus; Melphalan; Busulfan; Fludarabine

Type 2 Diabetes Mellitus, or Periodontal Disease Clinical Trial using non-surgical periodontal treatment; Supragingival biofilm control

University of Sao Paulo - Recruiting 30 years to 80 years.
- .
non-surgical periodontal treatment; Supragingival biofilm control

Myelodysplastic Syndrome, or MDS Clinical Trial using pracinostat; Azacitidine; Decitabine

MEI Pharma, Inc. - Recruiting 18 years or older.
- A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone.
pracinostat; Azacitidine; Decitabine

Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemi Clinical Trial using decitabine; mitoxantrone hydrochloride; etoposide; cytarabine; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming With Decitabine in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS): A Phase 1/2 Study.
decitabine; mitoxantrone hydrochloride; etoposide; cytarabine; laboratory biomarker analysis

Myelodysplastic Syndrome Clinical Trial

Samsung Medical Center - Recruiting 18 years or older.
- Retrospective Study for Predictive Marker for Decitabine Treament in MDS Patients.

Asthma Clinical Trial using Mometasone Furoate/Formoterol MDI 100/5 mcg; Mometasone Furoate/Formoterol MDI 200/5 mcg; Mometasone Furoate MDI 100 mcg; Mometasone Furoate MDI 200 mcg; Albuterol 90 mcg /salbutamol 100 mcg HFA MDI; Prednisone/prednisolone

Merck Sharp & Dohme Corp. - Recruiting 12 years or older.
- A 26-Week Randomized, Double-Blinded, Active Controlled Study Comparing the Safety of Mometasone Furoate/Formoterol Fumarate MDI Fixed Dose Combination Versus Mometasone Furoate MDI Monotherapy in Adolescents and Adults With Persistent Asthma (Protocol No. P06241 Also Known as P202).
Mometasone Furoate/Formoterol MDI 100/5 mcg; Mometasone Furoate/Formoterol MDI 200/5 mcg; Mometasone Furoate MDI 100 mcg; Mometasone Furoate MDI 200 mcg; Albuterol 90 mcg /salbutamol 100 mcg HFA MDI; Prednisone/prednisolone

Arthritis, Rheumatoid Clinical Trial using Etoricoxib 60 mg; Etoricoxib 90 mg; Placebo to Etoricoxib 60 mg; Placebo to Etoricoxib 90 mg

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase III, Two-Part, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Clinical Trial to Assess the Relative Efficacy and Tolerability of Two Doses of MK-0663/Etoricoxib in Patients With Rheumatoid Arthritis.
Etoricoxib 60 mg; Etoricoxib 90 mg; Placebo to Etoricoxib 60 mg; Placebo to Etoricoxib 90 mg

MDS, CMML, or AML Clinical Trial using SGI-110

Astex Pharmaceuticals - Recruiting 18 years or older.
- A Phase 1-2, Dose Escalation, Multicenter Study of Two Subcutaneous Regimens of SGI-110, a DNA Hypomethylating Agent, in Subjects With Intermediate or High-Risk Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML).
SGI-110

Melanoma Clinical Trial using MK-3475; Ipilimumab

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab in Patients With Advanced Melanoma.
MK-3475; Ipilimumab

Spondylitis, Ankylosing Clinical Trial using Part I - etoricoxib 60 mg; Part I - etoricoxib 90 mg; Part I- naproxen 1000 mg; Part I - Placebo to naproxen 500 mg; Part II- etoricoxib 60 mg; Part II- etoricoxib 90 mg; Part II- naproxen 1000 mg; Part I - Placebo to etoricoxib 60 mg; Part I - Placebo to etoricoxib 90 mg; Part II- Placebo to etoricoxib 60 mg; Part II - Placebo to etoricoxib 90 mg; Part II- Placebo to naproxen 500 mg

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase III, Two-Part, Randomized, Double-Blind, Active Comparator-Controlled, Multicenter Clinical Trial to Study the Relative Efficacy and Tolerability of Two Doses of MK-0663/Etoricoxib in Patients With Ankylosing Spondylitis.
Part I - etoricoxib 60 mg; Part I - etoricoxib 90 mg; Part I- naproxen 1000 mg; Part I - Placebo to naproxen 500 mg; Part II- etoricoxib 60 mg; Part II- etoricoxib 90 mg; Part II- naproxen 1000 mg; Part I - Placebo to etoricoxib 60 mg; Part I - Placebo to etoricoxib 90 mg; Part II- Placebo to etoricoxib 60 mg; Part II - Placebo to etoricoxib 90 mg; Part II- Placebo to naproxen 500 mg

Fungal Infections Clinical Trial using Posaconazole; Voriconazole

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase 3 Randomized Study of the Efficacy and Safety of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults (Phase 3; Protocol No. MK-5592-069).
Posaconazole; Voriconazole

Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Clinical Trial using cytarabine; daunorubicin hydrochloride; etoposide; pomalidomide; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years to 65 years.
- A Phase I Study of Pomalidomide Given at the Time of Lymphocyte Recovery Following Induction Timed Sequential Chemotherapy With Cytarabine, Daunorubicin and Etoposide (AcDVP16) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk MDS.
cytarabine; daunorubicin hydrochloride; etoposide; pomalidomide; laboratory biomarker analysis

Diabetes Mellitus, or Type 2 Diabetes Clinical Trial using Sitagliptin; Metformin; Placebo to sitagliptin; Placebo to metformin

Merck Sharp & Dohme Corp. - Recruiting 10 years to 17 years.
- A Phase III, Multicenter, Double-Blind, Randomized, Placebo and Metformin-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Sitagliptin in Pediatric Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control.
Sitagliptin; Metformin; Placebo to sitagliptin; Placebo to metformin

MDS (Myelodysplastic Syndrome), Myeloproliferative Disorder, Lymp Clinical Trial using Graft Manipulation (CD34+ Selection)

National Institutes of Health Clinical Center (CC) - Recruiting 2 years to 80 years.
- Peripheral Blood Stem Cell Allotransplantation For Hematological Malignancies Using Ex Vivo CD34 Selection - a Platform For Adoptive Cellular Therapies.
Graft Manipulation (CD34+ Selection)

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adul Clinical Trial using DEC-205/NY-ESO-1 fusion protein CDX-1401; poly ICLC; decitabine; laboratory biomarker analysis

Roswell Park Cancer Institute - Recruiting 18 years or older.
- A Phase I Study of DEC205mAb-NY ESO 1 Fusion Protein (CDX-1401) Given With Adjuvant polyICLC in Conjunction With 5-Aza-2'Deoxycytidine (Decitabine) in Patients With MDS or Low Blast Count AML.
DEC-205/NY-ESO-1 fusion protein CDX-1401; poly ICLC; decitabine; laboratory biomarker analysis

Acute Myeloid Leukemia, or Myelodysplastic Syndromes Clinical Trial using CD8+ T-cell depleted donor lymphocyte infusion

National University Hospital, Singapore - Recruiting 21 years to 90 years.
- Preemptive CD8+ T-cell Depleted Donor Lymphocyte Infusion (DLI) Following Nonmyeloablative Stem Cell Transplantation (NMT) for Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS).
CD8+ T-cell depleted donor lymphocyte infusion

Leukemia, Myeloid, Acute, or Myelodysplastic Syndromes Clinical Trial using decitabine

Washington University School of Medicine - Recruiting 18 years or older.
- Genomic Predictors of Decitabine Response in AML/MDS.
decitabine

Myelodysplastic Syndrome, MDS, or Trisomy 8 Clinical Trial using rigosertib

Onconova Therapeutics, Inc. - Recruiting 18 years or older.
- A Phase II, Multicenter, Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent Low or Intermediate-1 (Any Cytogenetics) or Trisomy 8 Intermediate-2 Myelodysplastic Syndrome Patients Based on IPSS Classification.
rigosertib

Myelodysplastic Syndrome Clinical Trial using SyB C-1101

SymBio Pharmaceuticals - Recruiting 20 years or older.
- Phase I Clinical Trial of SyB C-1101 in Patients With Myelodysplastic Syndrome.
SyB C-1101

Myelodysplastic Syndrome (MDS), or Severe Aplastic Anemia (SAA) Clinical Trial using Umbilical Cord Blood; Haploidentical Stem Cells; Miltenvi CliniMACs CD34 Reagent System

National Institutes of Health Clinical Center (CC) - Recruiting 4 years to 75 years.
- Co-Infusion of Umbilical Cord Blood and Haploidentical CD34+ Cells Following Nonmyeloablative Conditioning as Treatment for Severe Aplastic Anemia and MDS Associated With Severe Neutropenia Refractory to Immunosuppressive Therapy.
Umbilical Cord Blood; Haploidentical Stem Cells; Miltenvi CliniMACs CD34 Reagent System

Acute Myeloid Leukemia With Multilineage Dysplasia Following Myel Clinical Trial using WT1-sensitized T cells; aldesleukin; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting N/A or older.
- Phase I/II Study of Adoptive Immunotherapy After Allogeneic HCT With Virus Specific CD8+ T Cells That Have Been Transduced to Express a WT1-specific T Cell Receptor for Patients With High Risk or Relapsed AML, MDS, or CML.
WT1-sensitized T cells; aldesleukin; laboratory biomarker analysis

Hematological Malignancies, Acute Lymphoblastic Leukemia (ALL), A Clinical Trial using NiCordr

Gamida Cell ltd - Recruiting 18 years to 65 years.
- Allogeneic Stem Cell Transplantation of NiCordr, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells, in Adult Patients With Hematological Malignancies.
NiCordr

Myelodysplastic Syndrome Clinical Trial using Decitabine; Clofarabine

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Randomized Study of Decitabine Alternating With Clofarabine Versus Decitabine Until Failure in Patients With Higher Risk Myelodysplastic Syndromes (MDS).
Decitabine; Clofarabine

Leukemia, Myeloid, Chronic, AML, Leukemia, Lymphocytic, Acute, MD Clinical Trial using Stem Cell Transplant; Cyclophosphamide; Total Body Irradiation; Busulfan

Masonic Cancer Center, University of Minnesota - Recruiting N/A to 55 years.
- Allogeneic Transplant for Hematological Malignancy.
Stem Cell Transplant; Cyclophosphamide; Total Body Irradiation; Busulfan

Myelodysplastic Syndrome, MDS, or Anemia Clinical Trial using Lenalidomide; Eltrombopag

Albert Einstein College of Medicine of Yeshiva University - Recruiting 18 years or older.
- PHASE II STUDY OF LENALIDOMIDE AND ELTROMBOPAG IN PATIENTS WITH SYMPTOMATIC ANEMIA IN LOW OR INTERMEDIATE I MYELODYSPLASTIC SYNDROME (MDS).
Lenalidomide; Eltrombopag

Leukemia, or Myelodysplastic Syndromes Clinical Trial using clofarabine; cytarabine; idarubicin

European Organisation for Research and Treatment of Cancer - EORTC - Recruiting 18 years to 60 years.
- Clofarabine in Combination With a Standard Remission Induction Regimen (AraC and Idarubicin) in Patients 18-60 Years Old With Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS) : a Phase I-II Study of the EORTC-LG and GIMEMA (AML-14A Trial).
clofarabine; cytarabine; idarubicin

Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia Clinical Trial using allogeneic stem cell transplantation; 5-azacytidine until progress

Universit„tsklinikum Hamburg-Eppendorf - Recruiting 55 years to 70 years.
- Comparison Between 5-azacytidine Treatment and 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability.
allogeneic stem cell transplantation; 5-azacytidine until progress

Myelodysplastic Syndromes, or Juvenile Myelomonocytic Leukemia Clinical Trial

University Hospital Freiburg - Recruiting N/A to 215 Months.
- Prospective Non-randomized Multi-center Study for Epidemiology and Characterization of Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leucemia (JMML) in Childhood.